-
NPL re-launches to accelerate access to new health innovations
NPL, the UK’s National Measurement Institute, will re-launch this month to help ensure the UK continues to lead the world in translating life sciences research, accelerating access to new diagnosis and treatment techniques, and helping to support rapid adoption of advanced healthcare technologies across the country. This new approach will see NPL focus on tackling…
-
Synpromics Announces Gene Therapy Research Partnership with Solid Biosciences
Edinburgh, UK, 20th September 2017 / Sciad Newswire / Synpromics Ltd, the leader in gene control, today announces a new research partnership with Solid Biosciences, LLC. Under the terms of the agreement, Synpromics will provide Solid Biosciences access to a set of key muscle-selective promoter candidates to be used in the development of new treatment options for…
-
Press release story title: Cofactor Genomics announces $18M funding in an oversubscribed Series-A round to bring RNA to Precision Medicine
San Francisco, California, 19th September 2017 / Sciad Newswire / Cofactor Genomics, developer of a leading platform for RNA sequencing and expression analysis, today announced $18M in financing led by Menlo Ventures with major participation from existing investor Data Collective (DCVC) and new investor Ascension Ventures, and participation from existing and new investors iSelect, Y Combinator, Wilson Sonsini Goodrich…
-
Cypralis granted new Innovate UK feasibility stage award to develop cyclophilin inhibitors targeting fibrotic diseases
Cambridge, UK, 18th September 2017 / Sciad Newswire / Cypralis, a life sciences company focused on the discovery of therapeutics for the modulation of peptidyl-prolyl isomerases (PPIases), has been awarded new funding by Innovate UK, the UK’s innovation agency, under its BioMedical Catalyst competition. Cypralis has previously been awarded two other grants from Innovate UK that have…
-
Scientists present positive progress in the development of a new class of broad-spectrum organogold antibiotics
Poster and Oral Presentation at the 19th RSC / SCI Medicinal Chemistry Symposium, 10th-13th September 2017, Churchill College, Cambridge, UK Cambridge, UK, and Stevenage, UK, 12th September 2017 / Sciad Newswire / Domainex and Auspherix have announced new data from their collaboration to develop novel candidate drugs to tackle the growing threat of resistance to antibiotics. The exciting…
-
Synpromics expands facilities to meet demand for revolutionary gene control technology
Edinburgh, UK, 11th September 2017 / Synpromics Ltd, the leader in gene control and synthetic promoter development, today moves to new world-class facilities at the Roslin Innovation Centre. Synpromics is expanding to meet increasing global demand for its cutting-edge gene control technology, and is the first company to move into the new custom-built centre based…
-
Biotech and Money Awards Gala Dinner 2017
London, UK, 8th September 2017 / Sciad Newswire / On 14th September, 250 leading lights, emerging stars, C-suite executives, impactful investors and powerful stakeholders will be attending the Biotech and Money’s 2017 Awards Gala Dinner to celebrate and recognise the achievements of the UK’s Life Science sector over the last 12 months at one of London’s…
-
Connecting with Maria Patey, who joins the SCIAD team
It’s a small connected world, and through the exponential power of the internet and growth of social media, our personal and professional networks have never been stronger and therefore, opportunities for brands and businesses never greater! If you’ve not taken part in your own degrees of separation experiment, then I whole heartedly recommend it! If…
-
ReViral initiates Phase 2a study of RV521 for treatment of Respiratory Syncytial Virus
Challenge trial will evaluate RV521 in approximately 70 volunteers London, UK, 5th September 2017 / Sciad Newswire / ReViral, a UK-based biotech company focused on developing novel compounds targeting respiratory syncytial virus (RSV), announces that the first subjects have been dosed in a Phase 2a challenge study evaluating RV521 as an orally administered treatment for RSV infection….
-
Cambridge Research Biochemicals to licence novel fluorescent dyes with The University of Edinburgh for in vitro research and development use
Cleveland, UK, 31th August 2017 / Sciad Newswire / Cambridge Research Biochemicals® (CRB), offering over 37 years of expertise in the custom supply of research reagents, namely peptides and antibodies for life science research and development, today signed a licence agreement with Edinburgh Innovations, the Innovation Management Service for The University of Edinburgh. Under this new…